CM-4307
- Generic Name
- CM-4307
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 1130115-44-4
- Unique Ingredient Identifier
- 41XGO0VS1U
- Background
CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).
- Indication
用于治疗既往未接受过全身系统性治疗的不可手术切除或转移性肝细胞癌患者。
Robust Pipeline of 200+ Therapies Targets Colorectal Cancer Treatment Landscape
• DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.
• Key drug candidates include XL092 (Exelixis), Adagrasib (Mirati Therapeutics), Olaparib (Merck/AstraZeneca), and novel approaches like LYL845, an autologous tumor-infiltrating lymphocyte therapy from Lyell Immunopharma.
• The metastatic colorectal cancer segment shows particular promise with 150+ companies advancing 180+ pipeline therapies, including innovative treatments targeting specific mutations and immune pathways.
Novel Bispecific Antibody KN046 Plus Lenvatinib Shows Promise in Advanced Liver Cancer Treatment
• A phase II trial combining KN046, a bispecific antibody targeting PD-L1/CTLA-4, with lenvatinib achieved a 45.5% objective response rate in advanced hepatocellular carcinoma patients.
• The treatment demonstrated encouraging efficacy with median progression-free survival of 11.0 months and manageable safety profile, though 47.3% of patients experienced grade ≥3 treatment-related adverse events.
• Analysis revealed that circulating tumor DNA status early in treatment may serve as a potential biomarker for predicting treatment response and survival outcomes.
Innovent Highlights Promising Clinical Data on Novel Oncology Molecules at ESMO Asia 2024
• Innovent Biologics is set to present clinical data on multiple novel oncology molecules at the ESMO Asia Congress 2024, showcasing its commitment to innovative cancer therapies.
• Updated Phase 1 results of IBI343, a TOPO1i CLDN18.2 ADC, will be presented, demonstrating encouraging efficacy and safety in previously-treated pancreatic cancer patients.
• Additional studies feature combinations of sintilimab with chemotherapy and other agents, targeting various cancers including colorectal, liver, and non-small cell lung cancer.
• Innovent's robust pipeline and advanced technology platforms in immuno-oncology and antibody-drug conjugates aim to transform cancer treatment options for patients worldwide.
Innovent Highlights IBI343 Data in Pancreatic Cancer at ESMO Asia 2024
• Innovent will present clinical data on novel oncology molecules at the ESMO Asia Congress 2024, showcasing advancements in cancer treatment.
• Updated Phase 1 results of IBI343, a TOPO1i CLDN18.2 ADC, will be presented, demonstrating encouraging efficacy and safety in previously-treated pancreatic cancer.
• The company is also presenting data on combination therapies involving sintilimab and anlotinib in various cancer types, including colorectal and lung cancer.
• Innovent is dedicated to transforming cancer treatment by delivering innovative, effective, and safe therapeutic options for doctors and patients.
Conversion Therapy Shows Promise in Unresectable Hepatocellular Carcinoma
• Conversion therapy, combining systemic and local-regional treatments, shows promise in enabling R0 resection for initially unresectable hepatocellular carcinoma (uHCC).
• A real-world study reported a 1-2% conversion rate among uHCC patients, increasing to 2.59% with combination therapy, reflecting significant improvements in treatment opportunities.
• Patients undergoing successful conversion surgery had comparable survival prognosis to those undergoing direct R0 resection, suggesting potential long-term benefits.
• The study highlights the need for more precise criteria for defining clinical complete response (cCR) in HCC and longer-term research to fully understand the strategy's usefulness.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath